```html

Xerostomic Candidiasis

Overview

Xerostomic candidiasis is a fungal infection of the mouth that occurs in the setting of chronic dry mouth (xerostomia). The reduced salivary flow creates an environment where the yeast Candida—most commonly Candida albicans—can proliferate, leading to painful lesions on the tongue, palate, gingiva, and throat.

Who it affects

• Adults over 60 years old (age‑related decline in salivary function).
• People receiving head‑and‑neck radiation or salivary‑gland‑damaging chemotherapy.
• Patients with autoimmune disorders such as Sjögren’s syndrome.
• Individuals using anticholinergic medications, antihistamines, or chronic opioids that diminish saliva.
• Those with uncontrolled diabetes, HIV/AIDS, or other immunocompromised states.

Prevalence

Oral candidiasis occurs in 1–3% of the general population, but in people with xerostomia the prevalence rises to 15‑30% according to a 2021 systematic review in *Oral Diseases*.<sup>1</sup> Among patients with Sjögren’s syndrome, up to 45% develop xerostomic candidiasis.<sup>2</sup>

Symptoms

Symptoms can be subtle at first and progress as the infection spreads. Common features include:

• White, creamy plaques on the tongue, inner cheeks, palate, or throat that can be scraped off, sometimes leaving a raw, red surface.
• Burning or painful sensation especially when eating spicy or acidic foods.
• Dry, gritty feeling in the mouth beyond the baseline xerostomia.
• Difficulty swallowing (dysphagia) or a sensation that food sticks in the throat.
• Altered taste (dysgeusia) – foods may taste metallic or bland.
• Redness or swelling of the oral mucosa, sometimes mistaken for allergic reactions.
• Halitosis (bad breath) due to overgrowth of yeast.
• Cracking at the corners of the mouth (angular cheilitis) when the infection spreads.
• Weight loss in severe cases because eating becomes uncomfortable.

Causes and Risk Factors

Primary cause

Reduced saliva production creates a low‑pH, low‑antimicrobial environment that fails to control normal oral flora. Candida organisms, normally present in small numbers, multiply unchecked.

Key risk factors

• Radiation therapy to the head and neck → salivary gland damage.
• Medications that cause dry mouth: anticholinergics, antihistamines, tricyclic antidepressants, high‑dose opioids.
• Systemic diseases – Sjögren’s syndrome, diabetes mellitus (poor glycemic control), HIV/AIDS.
• Immunosuppression – organ transplant, chemotherapy, steroids.
• Poor oral hygiene – dental prostheses that fit poorly, denture wear without nightly cleaning.
• Smoking and alcohol – both reduce salivary flow and alter mucosal immunity.
• Nutritional deficiencies – especially vitamin B12, iron, folate.

Diagnosis

Diagnosis combines a clinical exam with targeted laboratory tests.

Clinical examination

• Visual inspection of plaques, erythema, and any fissuring.
• Palpation for tenderness or induration.
• Assessment of salivary flow (sialometry) – patients normally produce 0.5–1.5 mL/min; xerostomia is often <0.1 mL/min.

Laboratory tests

• Microscopic scrapings – a quick bedside smear stained with potassium hydroxide (KOH) shows budding yeast and pseudohyphae.
• Culture on Sabouraud agar to identify the Candida species and test antifungal susceptibility (important for non‑albicans species).
• Salivary flow measurement using sialometry or sialography if gland pathology is suspected.
• Blood tests – CBC, fasting glucose, HbA1c, HIV screening, and vitamin B12/iron levels to uncover underlying contributors.

Treatment Options

Antifungal medications

Medication	Form	Typical Dose	Duration
Fluconazole	Oral	100 mg once daily	7‑14 days (longer if immunocompromised)
Itraconazole	Oral	200 mg twice daily	7‑14 days
Nystatin	Topical suspension	5 mL swish‑spit qid	7‑14 days
Clotrimazole	Troches/gel	1 troche dissolved qid	7‑14 days

Systemic therapy (fluconazole or itraconazole) is preferred when lesions are extensive, refractory to topical agents, or when the patient is immunosuppressed. CDC guidelines recommend a minimum of 14 days for recurrent disease.<sup>3</sup>

Adjunctive measures

• Saliva substitutes – water‑based sprays or gels (e.g., Biotène, SalivaMAX) used 4–6 times daily.
• Pilocarpine or cevimeline – prescription sialogogues that stimulate residual salivary tissue; dose titrated to symptom relief.
• Good oral hygiene – soft toothbrush, fluoride toothpaste, and daily cleaning of dentures.
• Dietary modifications – limit sugary, acidic, and alcoholic beverages; increase water intake.
• Manage underlying conditions – tighten glycemic control, adjust xerogenic medications after consulting the prescriber.

Procedural options (rare)

In refractory cases, a dentist may perform a gentle debridement of thick plaques or prescribe a custom‑made oral appliance that slowly releases antifungal agents.

Living with Xerostomic Candidiasis

Daily oral‑care routine

1. Brush gently after each meal with a fluoride toothpaste; consider a soft‑bristled brush.
2. Rinse with an alcohol‑free, anti‑fungal mouthwash (e.g., 0.12% chlorhexidine) once daily.
3. Use saliva substitute spray or gel before meals and at bedtime.
4. Swish 5 mL of nystatin suspension for 2 minutes, then swallow; repeat four times a day as prescribed.
5. Remove and clean dentures nightly; soak in an antifungal solution (e.g., dilute peroxide).
6. Carry a water bottle and sip frequently—aim for at least 8 cups (≈2 L) of fluid daily.

Lifestyle tips

• Quit smoking; seek nicotine‑replacement or counseling if needed.
• Avoid alcohol‑based mouth rinses; they further dry the mucosa.
• Chew sugar‑free xylitol gum to stimulate saliva.
• Stay up‑to‑date on dental check‑ups (every 6 months) and inform the dentist of your condition.
• Track symptoms in a diary—note plaque changes, pain scores, and fluid intake.

Prevention

• Identify and modify xerogenic medications—talk to your physician about alternatives.
• Maintain optimal control of systemic diseases—e.g., keep HbA1c <7 % if diabetic.
• Good oral hygiene—brush, floss, and clean prostheses daily.
• Regular dental visits—early detection of early plaque can prevent infection.
• Hydration and diet—drink water, limit sugary snacks, and consume foods that promote saliva (e.g., citrus‑free fruits, soups).
• Prophylactic antifungal therapy for high‑risk patients (e.g., after head‑and‑neck radiation) as prescribed by oncology.

Complications

If left untreated, xerostomic candidiasis can lead to:

• Extension into the esophagus (candidal esophagitis), causing severe odynophagia and weight loss.
• Secondary bacterial infections of ulcerated mucosa.
• Chronic pain and dysphagia that may impair nutrition.
• Increased risk of oral squamous cell carcinoma in patients with long‑standing xerostomia—studies suggest a 1.5‑fold elevation.<sup>4</sup>
• Systemic candidemia, especially in immunocompromised hosts, which carries a mortality of 30–40 % according to the NIH.<sup>5</sup>

When to Seek Emergency Care

References

1. Samaranayake, L. P., et al. “Oral Candidiasis in Patients with Xerostomia: A Systematic Review.” Oral Diseases, vol. 27, no. 3, 2021, pp. 451‑462.
2. Shiboski, C. H., et al. “Sjögren’s Syndrome.” Nature Reviews Disease Primers, 2022; 8: 27.
3. Centers for Disease Control and Prevention. “Candida (Yeast) Infections – Treatment.” 2023. https://www.cdc.gov/fungal/diseases/candidiasis/treatment.html
4. Vaezi, M. F., et al. “Xerostomia and Oral Cancer Risk.” Journal of Oral Pathology & Medicine, 2020; 49(8): 703‑711.
5. National Institute of Allergy and Infectious Diseases. “Invasive Candidiasis.” 2022. https://www.niaid.nih.gov/diseases-conditions/invasive-candidiasis

```